Epidemiology and Management of Children with Hypertensive Crisis: A Single-Center Experience

Abstract

Most children who present with hypertensive crisis have a secondary cause for hypertension. This study describes the epidemiology and management of children with hypertensive crisis. A retrospective cohort study was done in a tertiary pediatric hospital from 2009 to 2015. Thirty-seven patients were treated for hypertensive crisis. Twelve (32.4%) patients were treated for hypertensive emergency. The majority of our patients (33 [89.1%]) had a secondary cause of hypertension. The most common identifiable cause of hypertension was a renal pathology (18/37 [48.6%]). Oral nifedipine (23 [62.1%]) was the most frequently used antihypertensive, followed by intravenous labetalol (8 [21.6%]). There were no mortalities or morbidities. Hypertensive crisis in children is likely secondary in nature. Oral nifedipine and intravenous labetalol are both effective treatments.

Keywords

hypertensive crisis - hypertensive emergency - pediatric

• References

• 1 Lee GH, Lee IR, Park SJ, Kim JH, Oh JY, Shin JI. Hypertensive crisis in children: an experience in a single tertiary care center in Korea. Clin Hypertens 2016; 22: 10
• 2 Gupta-Malhotra M, Banker A, Shete S. , et al. Essential hypertension vs. secondary hypertension among children. Am J Hypertens 2015; 28 (01) 73-80
• 3 Lurbe E, Agabiti-Rosei E, Cruickshank JK. , et al. 2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents. J Hypertens 2016; 34 (10) 1887-1920
• 4 Miyashita Y, Peterson D, Rees JM, Flynn JT. Isradipine for treatment of acute hypertension in hospitalized children and adolescents. J Clin Hypertens (Greenwich) 2010; 12 (11) 850-855
• 5 Flynn JT. Hypertension in the young: epidemiology, sequelae and therapy. Nephrol Dial Transplant 2009; 24 (02) 370-375
• 6 National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004; 114 (2 Suppl 4th Report): 555-576
• 7 Flynn JT, Kaelber DC, Baker-Smith CM. , et al; Subcommittee on Screening and Management of High Blood Pressure in Children. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics 2017; 140 (03) e20171904
• 8 Singh D, Akingbola O, Yosypiv I, El-Dahr S. Emergency management of hypertension in children. Int J Nephrol 2012; 2012: 420247
• 9 Yang WC, Lin MJ, Chen CY, Wu HP. Clinical overview of hypertensive crisis in children. World J Clin Cases 2015; 3 (06) 510-513
• 10 Stein DR, Ferguson MA. Evaluation and treatment of hypertensive crises in children. Integr Blood Press Control 2016; 9: 49-58
• 11 Thomas CA, Moffett BS, Wagner JL, Mott AR, Feig DI. Safety and efficacy of intravenous labetalol for hypertensive crisis in infants and small children. Pediatr Crit Care Med 2011; 12 (01) 28-32
• 12 Webb TN, Shatat IF, Miyashita Y. Therapy of acute hypertension in hospitalized children and adolescents. Curr Hypertens Rep 2014; 16 (04) 425
• 13 Yiu V, Orrbine E, Rosychuk RJ. , et al. The safety and use of short-acting nifedipine in hospitalized hypertensive children. Pediatr Nephrol 2004; 19 (06) 644-650
• 14 Egger DW, Deming DD, Hamada N, Perkin RM, Sahney S. Evaluation of the safety of short-acting nifedipine in children with hypertension. Pediatr Nephrol 2002; 17 (01) 35-40
• 15 Blaszak RT, Savage JA, Ellis EN. The use of short-acting nifedipine in pediatric patients with hypertension. J Pediatr 2001; 139 (01) 34-37